ChinaAMC SSE STAR Biology and Medicine ETF(588130.SH)

Company Encyclopedia

ChinaAMC SSE STAR Biology and Medicine ETF

588130.SH

Shareholder

Ownership	%Owned	Share Chg	Report Date
No Data

News

Shanghai Henlius Biotech Receives NMPA Approval for HLX701 Phase 1b/2 Clinical Trial Application

Shanghai Henlius Biotech Inc. has received approval from the National Medical Products Administration for its IND application for a phase 1b/2 clinical trial of HLX701, a recombinant human SIRPα-IgG4 Fc fusion protein injection, aimed at treating advanced colorectal cancer. This marks a significant step as no SIRPα-Fc fusion protein targeting CD47 has been approved globally. However, the company cautions that successful development and commercialization of HLX701 is not guaranteed, advising shareholders and potential investors to exercise caution.

Reuters·01/20/2026 16:58

Reuters·01/20/2026 16:58

Artera ranked 162 in Deloitte's 2025 Technology Fast 500 list. Several executive appointments announced.

Based in Santa Barbara, California, Artera.io has been acknowledged as the 162nd fastest-growing company in America. The company specializes in enhancing patient communications through the integration of human and AI agent intelligence. This recognition comes from Deloitte, as Artera.io secures a spot on the esteemed Technology Fast 500 list for the fifth year in a row.

Unusual Whales·01/21/2026 02:20

Unusual Whales·01/21/2026 02:20

"Large Firms" China Merchants Securities initiates coverage on Kanion Pharmaceutical, expects the impact of centralized procurement to be digested

China Merchants Securities has initiated coverage on Kanion Pharmaceutical, expecting net profits of RMB 1.65 billion, RMB 1.96 billion, and RMB 2.27 billion for the years 2025 to 2027, with annual growth rates of 1.5%, 18.9%, and 15.8%, respectively. The report indicates that Kanion Pharmaceutical has absorbed the impact of centralized procurement and has transformed into a full-chain innovative pharmaceutical company. Although there will be short-term performance fluctuations, the launch of innovative products starting in 2024 is expected to bring a turning point in performance. The company focuses on specialties and operates independently in skin health, ophthalmology, and Southeast Asian markets

AASTOCKS·01/21/2026 10:32

AASTOCKS·01/21/2026 10:32

Ascletis Unveils Potent Once-Monthly Triple Agonist ASC37 for Obesity Treatment

Ascletis Pharma Inc. has selected ASC37 injection, a next-generation GLP-1R/GIPR/GCGR triple peptide agonist, for clinical development targeting obesity and cardio-metabolic diseases. In studies, ASC37 showed a half-life of about 17 days, making it a potential once-monthly treatment. It was found to be significantly more potent than retatrutide. The company plans to submit an Investigational New Drug Application to the U.S. FDA in Q2 2026. This announcement has not yet been presented at a scientific meeting.

Reuters·01/20/2026 17:00

Reuters·01/20/2026 17:00